A diaziridine-based tumor-activated prodrug for AKR1C3-expressing cancers from a defunct Bay Area biotech.
OBI-3424
IV AKR1C3-activated cytotoxin prodrug Ph. I/II in advanced solid tumors prodrug of DNA cross-linking agent Br. J. Cancer, May 12, 2023 OBI Pharma, TW; Threshold Pharma, CA
Editor:
Loading...
